Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.
about
Epigenetics and Triplet-Repeat Neurological DiseasesAtaxia.Toward a therapy for mitochondrial diseaseThe promise and perils of HDAC inhibitors in neurodegenerationActivating frataxin expression by repeat-targeted nucleic acidsNicotinamide Administration Improves Remyelination after Stroke.Epigenetic promoter silencing in Friedreich ataxia is dependent on repeat length.Pharmacological treatments for Friedreich ataxia.Nicotinamide in Friedreich's ataxia: useful or not?Mechanism of Action of 2-Aminobenzamide HDAC Inhibitors in Reversing Gene Silencing in Friedreich's Ataxia.Epigenetic therapy for Friedreich ataxiaRepeat-mediated epigenetic dysregulation of the FMR1 gene in the fragile X-related disorders.Expanded GAA repeats impede transcription elongation through the FXN gene and induce transcriptional silencing that is restricted to the FXN locus.Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich's ataxia.Reversal of epigenetic promoter silencing in Friedreich ataxia by a class I histone deacetylase inhibitor.Annual meeting of the EpiGeneSys Network of Excellence--Advancing epigenetics towards systems biology.Simultaneous dual targeting of Par-4 and G6PD: a promising new approach in cancer therapy? Quintessence of a literature review on survival requirements of tumor cells.Cytokine therapy-mediated neuroprotection in a Friedreich's ataxia mouse modelMilestones in Friedreich ataxia: more than a century and still learning.Emerging therapies in Friedreich's ataxia.Friedreich Ataxia: current status and future prospects.Current concepts in the treatment of hereditary ataxias.Efficient Synthesis of Nicotinamide-1-¹⁵N for Ultrafast NMR Hyperpolarization Using Parahydrogen.Epigenetic Mistakes in Neurodevelopmental Disorders.Nicotinamide for skin cancer chemoprevention.Translating HDAC inhibitors in Friedreich's ataxia.Pharmacological therapeutics in Friedreich ataxia: the present state.GIFT-1, a phase IIa clinical trial to test the safety and efficacy of IFNγ administration in FRDA patients.Mesenchymal Stem Cell-Derived Factors Restore Function to Human Frataxin-Deficient Cells.Peptide SS-31 upregulates frataxin expression and improves the quality of mitochondria: implications in the treatment of Friedreich ataxia.Nicotinamide Inhibits Ethanol-Induced Caspase-3 and PARP-1 Over-activation and Subsequent Neurodegeneration in the Developing Mouse Cerebellum.Friedreich's ataxia: clinical features, pathogenesis and management.Activation of Frataxin Protein Expression by Antisense Oligonucleotides Targeting the Mutant Expanded Repeat.Long-term treatment with thiamine as possible medical therapy for Friedreich ataxia.Emerging therapeutics for the treatment of Friedreich’s ataxiaStratifying Heterogeneous Dimension of Neurodegenerative Diseases: Intervention for Stipulating Epigenetic Factors to Combat Oxidative Stress in Human Brain
P2860
Q26770705-C0A7231E-D984-40F3-86A9-8990DD5FB880Q27693329-68824E29-BCCA-4367-B2AD-EC382AC17733Q28080024-2F3B0936-78E5-4129-A3CC-59363E9E4103Q28087539-CF9DC2CA-B5D3-4736-AEB0-69E451F7C9E1Q28272901-569F66D0-4FAA-4930-8C18-A8175A8748C8Q33800897-CF4CCC14-15AD-462E-BFCC-E7C47FE04ECFQ34315338-AC7410AA-01DE-4178-B4B1-66F8144EEF5AQ34538823-6FD4F366-C3C2-42FE-ADB1-773C3147DCF4Q34846058-4BAEDF25-F625-4F03-8C06-7352CD729B5FQ35149824-2CE5397C-0A4C-4DE4-A22D-9B7E4EFE3B33Q35180607-393E2E05-687D-461D-AE10-54AA5C7F1E5AQ35675960-35473CF2-FD24-4B67-96DB-CB8E17F9E14DQ36302082-4623B7AB-5B6B-41D8-8D5F-4A6616EC1E5DQ36588584-E73822A8-9F04-4128-B057-312EADD448D4Q37021501-7A66398B-658E-4E84-97C7-02306303A007Q37272477-B6B32E14-9841-4CD7-9AA4-51ED3723EECCQ37417255-89FA92B0-0BF2-45A9-8248-A21B1F536CE8Q37663926-5966F62C-DAEF-4CDB-B1B9-8F40FA699F0BQ38348366-318AE549-B7B6-4225-AC03-202810EEFBFCQ38648895-61157658-4818-496C-8059-F00D5C17EF9CQ38730963-A3B58CF2-31D7-4821-987F-8D5AE24E4243Q38799644-C6A094F9-76F0-4751-802A-E94AAD7AF16CQ38892159-9ADE09C3-0325-40FF-A013-FF812C7F4CBFQ39159445-9A0EAB88-592B-4CA5-98E8-5728C2CAF889Q39189282-14732B0D-52AB-4A2B-8267-FFC971610656Q39230731-09E733FB-C5B1-42B2-AC7F-C85A45706BD9Q39445743-55FBEDFC-B39A-44D8-9C95-EF581F7A8E72Q40128798-FA1C080E-00A7-425C-B4B5-D641B6BE4EE9Q40956615-12200114-EF6F-4BEF-B1F4-9DD6226C6DAEQ41548664-ACAADF1A-21FD-4641-8B45-18A30774EE25Q47556627-07EF8BF8-071D-4B19-9FC9-EF1166419490Q47623823-F610A825-7CFB-4DCC-8F35-D57F64C41309Q50003880-6793CAF0-F3B8-401D-8CD2-A930E0834342Q51595921-FEA3E71B-EDB7-41B0-96E3-31DEE4FE4B24Q56700247-A153DBFD-74EF-487E-B636-CF50189DEFFEQ58051863-11F926B9-D484-4390-B358-5B0B8F989090
P2860
Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Epigenetic and neurological ef ...... -label, dose-escalation study.
@ast
Epigenetic and neurological ef ...... -label, dose-escalation study.
@en
Epigenetic and neurological ef ...... -label, dose-escalation study.
@nl
type
label
Epigenetic and neurological ef ...... -label, dose-escalation study.
@ast
Epigenetic and neurological ef ...... -label, dose-escalation study.
@en
Epigenetic and neurological ef ...... -label, dose-escalation study.
@nl
prefLabel
Epigenetic and neurological ef ...... -label, dose-escalation study.
@ast
Epigenetic and neurological ef ...... -label, dose-escalation study.
@en
Epigenetic and neurological ef ...... -label, dose-escalation study.
@nl
P2093
P50
P1433
P1476
Epigenetic and neurological ef ...... n-label, dose-escalation study
@en
P2093
Cihangir Yandim
Kin Tung Tam
Michael H Parkinson
Naomi Loyse
Ping Kei Chan
Richard Festenstein
Sophie Piper
Stavros Athanasopoulos
Tariq Mohammad
P304
P356
10.1016/S0140-6736(14)60382-2
P407
P577
2014-04-30T00:00:00Z